Nick Brandon
Chief Scientific Officer Neumora
Seminars
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- What recent Phase 2 and Phase 3 readouts have taught us about target validation in neuropsychiatric drug development?
- How can sponsors better address persistent challenges around placebo response, site quality and trial execution?
- To what extent do indication selection and patient population definitions influence the probability of success?
- How can biomarkers, precision psychiatry approaches and improved patient stratification help derisk future development programmes?
- What lessons from recent successes and setbacks should shape the next generation of neuropsychiatric clinical trials?
Thursday 17th September 2026
Advancing Therapeutics for Psychiatric Disease: Novel Targets & the Promise of Precision Neuroscience
1:30 pm
Thursday 17th September 2026
Panel Discussion: Redefining Therapeutic Potential in Muscarinics: Interrogating the M1/M4 Debate to Advance Next Generation Neuropsychiatric Treatments
3:00 pm
- What has Cobenfy taught us about the therapeutic potential of muscarinic mechanisms, and how should its success shape future drug development strategies?
- How should recent clinical readouts from selective M4 programs be interpreted, and what have they revealed about the opportunities and challenges of PAM-based approaches?
- To what extent do M1 and M4 receptor modulation contribute differently to efficacy, cognition, behavioural regulation and broader neuropsychiatric outcomes?
- How can developers address remaining translational challenges around dose selection, receptor occupancy, target engagement and biomarker development?
- Will M4 PAMs ultimately recapitulate the efficacy observed with M1/M4 agonist approaches, and what upcoming clinical readouts are most likely to answer this question?
- Looking ahead, where do muscarinic therapies have the greatest potential beyond schizophrenia, including psychosis associated with Alzheimer's disease and other neuropsychiatric disorders?
